General Surgery, The First affiliated Hospital of Shandong First Medical University, Jinan, Shandong, China.
Neurosurgery, The First affiliated Hospital of Shandong First Medical University, Jinan, Shandong, China.
J Gene Med. 2020 Oct;22(10):e3237. doi: 10.1002/jgm.3237. Epub 2020 Jun 21.
Long noncoding RNAs play influential roles in the progression of many types of human malignancies. The present study aimed to explore the prognostic value of long noncoding RNA FTX (FTX) on patients with glioma.
FTX expression in glioma specimens and matched adjacent non-neoplasm specimens was examined by a quantitative real-time polymerase chain reaction assay. Furthermore, assays of the relationships between FTX expression and clinicopathologic characteristics of patients with glioma were also performed. Kaplan-Meier methods were applied for the assays of the overall survival (OS) and progression-free survival (PFS) of patients and Cox regression assays were used to analyze the clinical value of FTX used as a possible biomarker.
FTX levels were significantly up-regulated in glioma specimens compared to the paired non-neoplasm specimens (p < 0.01). Furthermore, high FTX expression in neoplasm tissues was dramatically associated with World Health Organization grade (p = 0.001) and Karnofsky Performance Score (p = 0.009). Kaplan-Meier assays with 187 patients revealed that patients with high level of FTX expression displayed poorer OS (p = 0.002) and PFS (p = 0.000). Subsequently, multivariable Cox regression analysis identified FTX expression as an independent prognostic factor of unfavorable survivals in glioma (OS: p = 0.001; PFS: p = 0.002).
These findings indicated that FTX may be a novel predictor for prognostic assessment of glioma patients. However, studies conducted with larger numbers of patients are essential to confirm our findings.
长非编码 RNA 在多种人类恶性肿瘤的进展中发挥重要作用。本研究旨在探讨长非编码 RNA FTX（FTX）对胶质瘤患者的预后价值。
通过实时定量聚合酶链反应检测胶质瘤标本和配对的非肿瘤标本中的 FTX 表达。此外，还进行了 FTX 表达与胶质瘤患者临床病理特征之间关系的检测。Kaplan-Meier 法用于检测患者的总生存期（OS）和无进展生存期（PFS），Cox 回归分析用于分析 FTX 作为可能的生物标志物的临床价值。
FTX 水平在胶质瘤标本中明显高于配对的非肿瘤标本（p<0.01）。此外，肿瘤组织中高 FTX 表达与世界卫生组织分级（p=0.001）和卡氏功能状态评分（p=0.009）显著相关。对 187 例患者进行 Kaplan-Meier 分析显示，FTX 高表达的患者 OS（p=0.002）和 PFS（p=0.000）较差。随后，多变量 Cox 回归分析表明，FTX 表达是胶质瘤不良生存的独立预后因素（OS：p=0.001；PFS：p=0.002）。
这些发现表明，FTX 可能是评估胶质瘤患者预后的一个新的预测因子。然而，需要进行更大数量患者的研究来证实我们的发现。
